This result implies that DDX17 could potentially influence hepatic macrophage activation and may even promote the progression of NASH‐HCC by remodelling the tumour‐prone liver microenvironment. This evidence concerns the gene DDX17 and metabolic dysfunction-associated steatohepatitis.